Pear Therapeutics announced today that it entered into multiple agreements to bolster its prescription digital therapeutics (PDT) platform.
Boston-based Pear Therapeutics’ agreements are set to add to its library of digital biomarkers, machine learning algorithms, sensor-based technologies and digital therapeutics, according to a news release.
Get the full story at our sister site, Drug Delivery Business News.